Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026
PR Newswire•04/11/2026•08:35 ET
2
Key Highlights
- ➤ESMO presentation scheduled December 14 for Anixa’s ovarian cancer CAR-T trial
- ➤Fifth cohort completed at 1x10⁷ CAR-positive cells/kg, 100-fold above initial dose
- ➤Sixth cohort planned at 1x10⁸ CAR-positive cells/kg after routine safety verification
- ➤No dose-limiting toxicities observed to date in the Phase 1 study
- ➤Preliminary observations include stable disease at 90 days and four survivors beyond one year
Expert Statements
Amit Kumar, Chairman and CEO of Anixa Biosciences
“We are pleased that Dr. Wenham will be presenting our ovarian cancer CAR-T clinical program at this important international immuno-oncology conference.”
Amit Kumar, Chairman and CEO of Anixa Biosciences
“Our trial continues to advance through progressively higher dose levels as well as lymphodepletion, and we are encouraged by the safety profile and preliminary clinical observations reported to date.”
Amit Kumar, Chairman and CEO of Anixa Biosciences
“The completion of our fifth cohort represents another important step in evaluating this novel approach to treating recurrent ovarian cancer.”
Amit Kumar, Chairman and CEO of Anixa Biosciences
“We look forward to sharing our progress with the international oncology community as we continue working with our colleagues at Moffitt to advance this promising therapy.”
Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026 PR Newswire
Dr. Robert Wenham, principal investigator of Anixa's Phase 1 clinical trial at Moffitt Cancer Center, to present on December 14 in London
Get started
Create a free account to read the full story.